Active Filters
- Press ReleaseClear filter
Jan 30, 2023
S1416 trial results show PARP inhibitor benefit in "BRCA-like" triple-negative breast cancer
Jan 20, 2023
Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some
Dec 19, 2022
Four decades of NCI-funded NCTN trials gave U.S. patients 14.2 million life-years for a federal investment of $326 per life-year gained
Nov 23, 2022
Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
Nov 21, 2022
SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.
Nov 3, 2022
Adding stratification factors can reduce a small trial’s statistical power
Oct 25, 2022
Sep 11, 2022
SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.